<p><b>TABLE OF INTERACTIONS WITH </b></p>

<p><b>CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, pp. 18-19</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C01B-003</b></p></td>
<td valign="top"><p><b>BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-001</b></p></td>
<td valign="top"><p>Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and EKG</p>

<p><b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C01B-003</b></p></td>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p>Negative inotropic effect with risk of acute decompensated heart failure </p>

</td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

